The Pharmacy Times® Oncology Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to oncology pharmacists.
August 23rd 2025
Patients in an outpatient oncology unit expressed willingness to receive a pneumococcal or influenza vaccine from a pharmacist if offered.
FDA Approves Abraxane as a First-Line Treatment for Advanced Non-Small Cell Lung Cancer
October 12th 2012Celgene Corporation today announced the FDA has approved Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) as a first-line treatment for locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
Read More
Symptom Relief from Breakthrough Cancer Pain: An Evaluation of Patient Satisfaction
September 13th 2012Breakthrough cancer pain-episodes of intense pain experienced by many cancer patients despite around-the-clock treatment with opioids-can be effectively managed with a fentanyl-based oral spray.
Read More
New FDA Actions: Genetech's Erivedge
September 12th 2012The FDA approved Genetech's Erivedge (vismodegib) capsules for the treatment of adult patients with metastatic basal cell carcinoma(BCC) or with locally advanced BCC that has recurred following surgery, and for patients who are not candidates for radiation.
Read More
FDA Approves Afinitor for Advanced Breast Cancer
July 23rd 2012The United States Food and Drug Administration recently approved Afinitor (everolimus) for use in combination with Aromasin (exemestane) to treat certain postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer.
Read More
FDA Approves Myeloma Drug for Certain Patient Populations
July 20th 2012The United States Food and Drug Administration today approved Kyprolis (carfilzomib) to treat patients with multiple myeloma who have received at least 2 prior therapies, including treatment with Velcade (bortezomib) and an immunomodulatory therapy.
Read More